GSK Adult RSV Vaccine: 3 Things Primary Care Clinicians Should Remember
Medical director of the NFID William Schaffner, MD, shares 3 things about the RSV vaccine that should be top of mind for primary care clinicians.
Daily Dose: Prediabetes, Intervening Diabetes, & Subsequent Dementia Risk
Your daily dose of clinical news you may have missed.
Younger Age at Diabetes Onset Associated with Higher Risk of Dementia, According to New Study
Results also showed that prediabetes is associated with dementia risk but this risk was explained by the subsequent development of diabetes.
Daily Dose: Adherence to GLP1RA, SGLT2i Therapies & Prescription Copayment Level
Seen in the ED: Intractable Vomiting in a Young Woman
The patient is in her mid-20s and other than an intermittent mild headache she denies any other pain and has no fever. Can you Dx based on the CT?
Endocrine Society Recommendations on How to Avoid Hypoglycemia in Patients with Diabetes: A Guideline Topline
The Endocrine Society's first update on management of hypoglycemia since 2009 emphasizes the value of new technology and therapeutics in minimizing risk.
Lower Adherence with GLP1RA, SGLT2i Therapies Linked to Higher Prescription Copayments
In a new study of adults with T2D and/or HF, those with higher prescription copayments were less likely to achieve 1-year adherence to GLP1-RA and SGLT2i therapies.
FDA Posts Warning on Compounded Semaglutide Products, Citing Reports of Adverse Events
Compounded versions of semaglutide, often sold online, may contain salt versions of the molecule and are not evaluated by the FDA for safety or efficacy.
The Long COVID Neuro Differential Dx: Sometimes Tricky, Always Nuanced
Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.
Long COVID Typically Presents in Symptom Clusters, Rarely as a Single Complaint, Expert Explains
A Feinberg School of Medicine physiatrist with long experience assessing long COVID talks specifically about common neurologic sequelae of the infection.
Friday's 5 Quotes for Primary Care 6-2-2023
The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.
Daily Dose: Subclinical CVD Affects 1 in 3 US Adults with Diabetes
Pfizer Wins FDA Approval for Vaccine against RSV in Older Adults
The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.
Long COVID was Apparent by Summer 2020 and in a Wide Range of Patients
Symptoms of long COVID were apparent by the summer of 2020, said physiatrist Dr Leslie Rydberg, coauthor of new consensus guidelines on management of neurologic sequelae.
One in 3 US Adults with T2D Shows Evidence of Subclinical CVD Based on Cardiac Biomarkers
As indicated by levels of 2 common biomarkers of cardiac injury, 33.4% of US adults with T2D showed evidence of undetected CVD vs only 16.1% of those without T2D.
Landmark NIH Study: Symptom-based Scoring System May Help Diagnose Long COVID
Researchers found a total of 12 symptoms that contributed to the long COVID scoring system.
Daily Dose: Disparities in Diabetes Care
FDA Approves First Oral Antiviral Medication for COVID-19 Treatment among Adults
The FDA approved Paxlovid™ for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease.
FDA Approves SGLT-2/1 Inhibitor Sotagliflozin, Grants Broad Heart Failure Indication
The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.
Comorbidities Associated with COPD Affect Outcomes, Require Attention
At the 2023 American Thoracic Society International Conference a symposium focused on common comorbidities seen with COPD, their management, and research needs.
.jpeg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "FDA Approves First Oral Antiviral Medication for COVID-19 Treatment among Adults")
